{"search_session":{},"preferences":{"l":"ru","queryLanguage":"ru"},"patentId":"080-572-126-397-652","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"080-572-126-397-652"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8759,"type":"PATENT","title":"University of Columbia","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":13487,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8203,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
(a) determining the presence of a radioactive signal from an administered radioligand in at least one individual in a control group and at least one individual in a reference group to generate primary brain scan image voxel data of radioligand distribution in a brain of at least one individual in a control group and at least one individual in a reference group,\n
(b) generating secondary brain scan image data for the individuals in the control and reference groups, wherein the secondary scan brain image data is generated using a different type of brain scan than the primary brain scan image data,\n
(c) generating a probability-corrected time-activity curve data for each voxel in the primary brain scan image of the at least one individual in the control and reference group,\n
(d) processing the probability-corrected time-activity curve data of the at least one individual in the control and reference group to generate a voxel binding outcome map data of the at least one individual in the control and reference group,\n
(e) transforming the voxel binding outcome map data of the at least one individual in the control and reference group into a normalized space to generate a normalized voxel binding outcome map data of the at least one individual in the control and reference group\n
(f) processing the normalized voxel binding outcome map data of the at least one individual in the control and reference group using statistical analysis to identify one or more voxels of interest (VOI) in the normalized voxel binding outcome map data to generate a VOI map data for differentiating of the at least one individual in the control and reference group, and\n
(g) applying the VOI map data to a voxel binding outcome map data of a test subject to generate a mean cortical binding value to diagnose or determine risk of a neurological disorder in the subject wherein the voxel binding outcome map data of said test subject is generated from Positron Emission Tomography (PET) using a PET scanner."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the transforming of step (e) comprises transforming the voxel binding outcome map data of the at least one individual in the control and reference group into a secondary scan space to generate a secondary space voxel binding outcome map data of the at least one individual in the control and reference group."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein step (g) comprises:\n
(i) inverse transforming the VOI map data identified in step (f), into a secondary scan space of the test subject to generate a voxel of interest (VOI) mask for the test subject,\n
(ii) multiplying the VOI mask for the subject by probabilistic brain region (BRP) map data for the subject to generate a brain region VOI mask for the subject,\n
(iii) multiplying a secondary space voxel binding outcome map data of the subject by the brain region VOI mask for the subject to generate cortical binding map data for the subject, and\n
(iv) summing the cortical binding map data of the subject and then dividing it by the sum of the brain region VOI mask to generate a mean cortical binding value."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, wherein the method further comprises a step of processing the secondary brain scan image data of the subject by partial volume correction analysis."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the generating a probability-corrected time-activity curve data for each voxel in the primary brain scan image of the at least one individual in the control and reference group in step (c) comprises:\n
(i) processing the secondary brain scan image data of the at least one individual in the control and reference group to generate a binary brain region mask and probabilistic brain region (BRP) map data for each individual, and\n
(ii) processing the probabilistic brain region (BRP) map data and the primary brain scan image data of the at least one individual in the control and reference group onto the binary brain region mask of the individual to generate the a probability-corrected time-activity curve data for each voxel in the primary brain scan image of the at least one individual in the control and reference group."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the normalized voxel binding outcome map data of the at least one individual in the control and reference group is generated by transformation of secondary space voxel binding outcome map data of the individual into a standard brain atlas."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the standard brain atlas is a Talairach brain atlas or a Montreal Neurological Institute (MNI) brain atlas."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the standard brain atlas is a specific brain atlas created for a particular neurological disorder."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the standard brain atlas is a custom brain atlas."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, wherein the inverse transforming is performed using parameters from an MRI to standard brain atlas registration."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the processing in step (f) comprises:\n
(i) generating a binary voxel image mask of the at least one individual in the control and reference group by statistical parametric mapping analysis,\n
(ii) inverse transforming the binary voxel image mask of the at least one individual in the control and reference group into a secondary space voxel binding outcome map data of the individual to generate a voxel of interest (VOI) mask,\n
(iii) multiplying the VOI mask of the at least one individual in the control and reference group by the individual's probabilistic brain region (BRP) map data and secondary space voxel binding outcome map data to generate cortical binding map data for the individual,\n
(iv) dividing the sum of the cortical binding map of the at least one individual in the control and reference group and the reference group by the mean of the probabilistic brain region (BRP) map data of the individual to generate a mean cortical binding outcome value for the statistical parametric mapping analysis applied in step (i),\n
(v) performing statistical analysis between the mean cortical binding outcome values of the at least one individual in the control and reference group to generate a map assigning a probability value to each voxel, and\n
(vi) identifying a scoring threshold providing maximal separation of mean cortical binding outcome values between the at least one individual in the control and reference group, wherein the VOI corresponding to the scoring threshold providing maximal separation of mean cortical binding outcome between individuals from the control group and individuals from the reference group is a VOI map data suitable for differentiating individuals in the reference group from individuals in the control group."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3 or 11, wherein the secondary space voxel binding outcome map data is generated using a different type of brain scan than the primary brain scan image data used in step (a) of claim 1."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the statistical analysis in step (v) is a Student's t test."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the generating of the binary voxel image mask in step (i) comprises applying one or more threshold values to the normalized voxel binding outcome map data such that, for each threshold, data in the voxel binding outcome map data equal to or exceeding the threshold value are retained in the binary voxel image mask and data in the voxel binding outcome map data less than the threshold value are not retained in the binary voxel image mask."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the one or more threshold values are greater or equal to a value of 50% mean cortical binding outcome in each voxel in the normalized voxel binding outcome map data."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the one or more threshold values are greater or equal to a value of 90% mean cortical binding outcome in each voxel in the normalized voxel binding outcome map data."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the one or more threshold values are greater or equal to a value of 99% mean cortical binding outcome in each voxel in the normalized voxel binding outcome map data."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the primary brain scan image data is generated using an arterial input function as a reference."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the secondary brain scan image data is from the cerebellum of the individual."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the secondary brain scan image data is from one or more regions of the cerebellum."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the secondary brain scan image data is from one or more regions of having reduced radioligand binding."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the transforming the voxel binding outcome map data of the at least one individual in the control and reference group into a normalized space comprises co-registration."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the processing in step (c) comprises Logan graphical analysis."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 23, wherein a brain region probability corrected time activity curve of the cerebellum is used as a reference region."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, 5, 11 or 24, wherein the brain region is gray matter."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, 5, 11 or 24, wherein the brain region is white matter."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, 5, 11 or 24, wherein the brain region is cerebrospinal fluid."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, 5, 11 or 24, wherein the brain region is a brain region comprising one of more voxels in step (c) of claim 1."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the normalized space voxel binding outcome map data is processed by partial volume correction before step (g)."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 29, wherein the partial volume correction analysis comprises a three-compartment method."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 29, wherein the partial volume correction analysis comprises a two-compartment method."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the transforming in step (e) is performed using an algorithm selected from the group consisting of any of Statistical Parametric Mapping (SPM), Simple Affine (AFF) methodology, the Fifth Order Polynomial Warp (WRP) methodology, and the Full Multi Grid (FMG) methodology."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the transforming in step (e) is performed using an algorithm is selected from the group consisting of AIR, ANIMAL, ART, Diffeomorphic Demons, FNIRT, IRTK, JRD-fluid, ROMEO, SICLE, SyN and FLIRT."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein individuals in the control group and the reference group are separated into groups according to the presence or absence of a neurological disorder."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the neurological disorder is Alzheimer's disease."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the neurological disorder is a reduced responsiveness to a compound administered to the subject as compared to a control subject."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the neurological disorder is an increased responsiveness to a compound administered to the subject as compared to a control subject."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 36 or 37, wherein the compound is a selective serotonin reuptake inhibitor."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the neurological disorder is selected from the group consisting of mild cognitive impairment, Dementia, Alzheimer's disease, multi-infarct dementia, Pick's disease, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, AIDS dementia complex, frontotemporal dementia, sundowning, wandering, delirium, post-concussion syndrome, organic brain syndrome, intoxication/drug overdose, physical dependence, substance dependence, rebound effect, double rebound, withdrawal, psychosis (e.g. schizoaffective disorder, schizophreniform disorder, brief reactive psychosis), schizophrenia (e.g. disorganized schizophrenia, delusional disorder, folie à deux), mood disorders, mania, bipolar disorders (e.g. bipolar I, bipolar II, cyclothymia, bipolar NOS), depression (e.g. major depressive disorder, dysthymia, seasonal affective disorder, atypical depression, melancholic depression), anxiety disorders, phobias, panic disorder/panic attack, generalized anxiety disorder, OCD, stress disorders (e.g. acute stress reaction, PTSD), adjustment disorder with depressed mood, somatoform disorders, somatization disorder, body dysmorphic disorder, hypochondriasis, nosophobia, Da Costa's syndrome, psychalgia, conversion disorders (e.g. Ganser syndrome, Globus pharyngis), neurasthenia, mass psychogenic illness, dissociative disorders, dissociative identity disorder, psychogenic amnesia, fugue state, depersonalization disorder, eating disorders, anorexia nervosa, bulimia nervosa, rumination syndrome, NOS, nonorganic sleep disorders, nonorganic hypersomnia, nonorganic insomnia, parasomnia disorders (e.g. REM behavior disorder, night terror, nightmare), sexual dysfunction, sexual desire disorders (e.g. hypoactive sexual desire disorder, hypersexuality), sexual arousal (e.g. female sexual arousal disorder), erectile dysfunction, orgasm disorders (e.g. anorgasmia, premature ejaculation), postpartum depression, postnatal psychosis, adult personality and behavior disorders, sexual maturation disorder, ego-dystonic sexual orientation, sexual relationship disorder, paraphilia disorders (e.g. voyeurism, fetishism), personality disorder, impulse control disorder (e.g. kleptomania, Trichotillomania, Pyromania), body-focused repetitive behavior, factitious disorders (e.g. Munchausen syndrome), mental retardation, phychological development disorders, ADHD, conduct disorders (e.g. ODD), emotional disorders (e.g. Separation anxiety disorder), social functioning disorders (e.g. selective mutism, RAD, DAD), tic disorders (e.g. Tourette syndrome), speech disorders (e.g. stuttering, cluttering), movement disorders (e.g. stereotypic movement disorder), catatonia, false pregnancy, intermittent explosive disorder, psychomotor agitation, sexual addiction, stereotypy, psychogenic non-epileptic seizures, Klüver-Bucy syndrome, Emil Kraepelin mood disorder, Karl Leonhard mood disorder, John Cade mood disorder, Mogens Schou mood disorder, Frederick K. Goodwin mood disorder, Kay Redfield Jamison mood disorder, hallucination, delusion, emotional dysregulation disorders (e.g. anhedonia, dysphoria, suicidal ideation), sleep disorders (e.g. hypersomnia, insomnia), psychosis, and racing thoughts."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 36 or 37, wherein the compound is selected from the group consisting of an analgesic, an anesthetic, an anorectic, an anti ADHD agent, an antiaddictive, an anticonvulsant, an antidementia agent, an antidepressant, an antimigraine agent, an antiparkinson's agent, an antipsychotic, an anxiolytic, a depressant, an entactogen, an entheogen, an euphoriant, a hallucinogen, hypnotics/sedative, a mood stabilizer, a neuroprotective, a nootropic, a neurotoxins, an orexigenic, a serenic, a stimulant, and a wakefulness-promoting agent."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising a step of administering the radioligand to the one or more individuals in the control group and to the one or more individuals in the reference group before step (a)."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the radioligand is N-methyl-[11C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the radioligand is [11C] WAY-100635."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the radioligand is selected from the group consisting of [11C]-DTBZ, 11CFE-CIT, [18F]-dopa, [11C]-dopa, [18F]-CFT, [11C]-RTI-32, [18F]-FP-CIT, [11C]-methylphenidate, [123I]-β-CIT, [123I]-FP-CIT, [123I]-altropane, [99mTc]-TRODAT-1, [11C]-dihydrotetrabenazine, [99mTc]-MHMPAO, [99mTc]-ethylcystein dimer, [99mTc]-DTPA, [99mTc]-glucoheptonate, [99mTc]-sestamibi, [99mTc]-tetrofosmin, [99mTc]-labelled sulphur colloid, H215O, [18F]-fluorodeoxyglucose, [13N]-ammonium, [15O]-butanol, 11Xe, 15O2, [11C]-CFT, [123I]-IPT, [11C]-SCH23390, [11C]-raclopride, [11C]-FLB456, [11C]-methylspiperone, [18F]-spiperone, [18F]-fluroethylspiperone, [76Br]-bromospiperone, [123I]-eppidepride, [123I]-iodobenzamide, [11C]-BATA, [18F]-2-fluorothoxydazoxan, [11C]-methyltryptophan, [11C]-DASB, [11C]-MDL100907, [18F]-altanserin, [18F]-serpeptone, [11C]-MP4A, [11C]-physostigmine, [18F]-fluoroethozybenzoessamicol, [11C]-vesamicol, [123I]-benzovesamicol, [11C]-tropanylbenylate, [11C]-NMPB, [18F]-FP-TZTP, [123I]-QNB, [11C]-MPA, [11C]-A-85380, [18F]-A-85380, [123I]-A-85380, [11C]-dothiepin, [11C]-carfentenil, [18F]-cyclofoxy, [11C]-diprenorphine, [11C]-flumazenil, [11C]-R015-4513, [11C]-PK11195, [18F]-PK11195, [123I]-PK11195, [18F]-SPARQ, [11C]-GR205171, [11C]-SCH 442416, [11C]-CNS 5161, [18F]-FDDNP, [11C]-SB13, [123I]-IMPY, and [11C]-carfentenil."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the primary brain space image is generated using Positron Emission Tomography."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the secondary brain space image is generated using Magnetic Resonance Imaging."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the binding outcome is a specific-to-nonspecific equilibrium partition coefficient (BPND)."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the binding outcome is a binding potential relative to plasma (BPP)."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the binding outcome is a binding potential relative to free plasma concentration (BPF)."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the binding outcome is standardized uptake value (SUV)."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the binding outcome is determined by a standardization technique that generates a qualitative or quantitative measure of radioligand uptake or binding."],"number":51,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}